Price
$3.76
Decreased by -1.31%
Dollar Volume
2.35 M
ADR%
11.09
Earnings Report Date (estimate)
Nov 14, 22 (N/A)
Market Cap.
64.58 M
Shares Float
4.56 M
Shares Outstanding
5.95 M
Beta
1.26
Price / Earnings
0.10
BPR
18.44
20D Range
3.25 4.90
50D Range
2.70 5.79
200D Range
2.70 9.25
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -1.48
Increased by +15.43%
-1.75
Increased by +15.43%
Aug 11, 22 -2.08
Increased by +48.00%
-1.87
Decreased by -11.23%
May 13, 22 -3.50
Increased by +12.50%
-2.25
Decreased by -55.56%
Mar 31, 22 -3.50
Increased by +17.65%
-3.75
Increased by +6.67%
Nov 15, 21 -1.75
Increased by +58.82%
-4.00
Increased by +56.25%
Jul 29, 21 -4.00
Decreased by -100.00%
-4.00
Jul 28, 21 -4.00
Decreased by -14.29%
-4.00
May 18, 21 -4.25
Increased by +67.31%
-4.75
Increased by +10.53%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-9.48 M
Decreased by -34.64%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 1.00 M
Increased by +N/A%
-8.29 M
Increased by +45.45%
Decreased by -829.50%
Decreased by N/A%
Mar 31, 22 346.00 K
Increased by +N/A%
-20.79 M
Decreased by -29.93%
Decreased by -6.01 K%
Decreased by N/A%
Dec 31, 21 3.00 M
Increased by 0.00%
-46.68 M
Decreased by -194.94%
Decreased by -1.56 K%
Decreased by -194.94%
Sep 30, 21 0.00
Decreased by -100.00%
-7.04 M
Increased by +2.67%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-15.21 M
Decreased by -16.89%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-16.00 M
Increased by +66.77%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 3.00 M
Increased by +N/A%
-15.83 M
Increased by +3.67%
Decreased by -527.60%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.